Browse News
Filter News
Found 650,481 articles
-
The date set by the FDA’s independent advisors for debating that decision is Friday, February 26.
-
Although problems with actually getting shots into arms have been described thoroughly, manufacturing problems and scale-up haven't been the focus of much reporting.
-
Mallon announced his resignation from Ironwood earlier this month to take on a new leadership opportunity and “pursue multiple passions.”
-
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
-
Money on the Move: February 17-23
2/24/2021
Life sciences companies across the globe are raking in investment dollars to advance drug programs. -
The hold comes just after patient dosing began in HGB-210, the company’s Phase III single-arm open-label LentiGlobin trial for SCD patients between the ages of 2 and 50.
-
The prosecution alleged that sometime in 2018, Holmes destroyed a database called the Laboratory Information System (LIS), which contained three years’ worth of accuracy and failure rates of Theranos tests.
-
The Fralin Biomedical Research Institute (FBRI) at Virginia Tech Carilion (VTC) replaced its information technology (IT) system as one of the foundational steps that, within the next few years, will allow the research center to double its research capacity with the addition of more than 25 new labs.
-
Doppler Technique Allows Researchers to “Peek” Into Cells, Identify Antibiotic-Resistant Pathogens
2/24/2021
Scientists from Purdue University are using Doppler radar to “peek” into cells and monitor metabolic activity in real time, allowing them to test microbes, detect pathogens in different environments and identify potential treatments for antibiotic-resistant bacteria. -
Even with its potential technical advantages, Novavax has some challenges.
-
BMS is looking to hire "several hundred employees over the next few years," all working to ensure the production of both their clinical and commercial cell therapies.
-
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
2/24/2021
- LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December 31, 2020 – - Conference call to be hosted today at 4:30 p.m. ET -
-
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
2/24/2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.
-
Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights
2/24/2021
- Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalimab’s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus’s FcR-enabled anti-TIGIT antibody, reinforces Arcus’s position as a leader in the anti-TIGIT field - Promising early data in first-line metastatic pancreatic cancer for AB680, the first small-molecule CD73 inhibitor to enter clinical development,
-
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
2/24/2021
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates
-
DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes
2/24/2021
DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030 (the "notes").
-
West Announces Second-Quarter 2021 Dividend
2/24/2021
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2021 dividend of $0 .17 per share. The dividend will be paid on May 5, 2021, to shareholders of record as of April 21, 2021
-
Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China
2/24/2021
Joint Venture Will Enable Cerus to Partner with Leader in Transfusion Medicine to Bring INTERCEPT to the Mainland China Transfusion Market
-
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
2/24/2021
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").
-
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
2/24/2021
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the peer-reviewed publication of a study investigating the effects of the co-administration of ImmTOR nanoparticles to adeno-associated viral (AAV) vectors on transgene expression in mice